Goldman Sachs Upgrades Myriad Genetics (MYGN) to Neutral

Goldman Sachs analyst Patrick Donnelly upgraded Myriad Genetics (NASDAQ: MYGN) from Sell to Neutral with a price target of $32.00 (from $28.00).

The analyst feels the valuation is now more balanced.

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $32.05 yesterday.

You May Also Be Interested In

• Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
• Jefferies Downgrades IDP Education (IEL:AU) (IDPUF) to Hold
• Shanghai Conant Optical (2276:HK) PT Lowered to HK$81.40 at Macquarie